Cagrilintide 10mg Lyophilized Powder

CAS Number: 1415456-99-3

Molecular Formula: C194H312N54O59S2

Molecular Weight: $4409.01 g/mol

Sequence: Acylated long-acting peptide derivative of human amylin with a intramolecular Cys3-Cys8 disulfide bridge

Purity: >99% (Verified by HPLC & MS)

Specification: 10mg Lyophilized Solid / Single-Vial Laboratory Specimen

Overview & Primary Mechanism of Action

Cagrilintide 10mg is a high-purity, laboratory-grade synthetic peptide engineered for advanced research into metabolic signaling and central appetite regulation. Classified as a long-acting Dual Amylin and Calcitonin Receptor Agonist (DACRA), Cagrilintide mimics the endogenous neuroendocrine hormone amylin while benefiting from strategic structural modification (lipidation) that dramatically extends its half-life.

Unlike standard single-target metabolic peptides, Cagrilintide operates via dual receptor co-engagement:

1. Amylin Receptors : cagrilintide acts as an agonist at the heteromeric amylin receptor complexes (formed by the calcitonin receptor core bound to RAMP1, RAMP2, or RAMP3). Signal transduction through the hindbrain (area postrema and nucleus tractus solitarius) activates homeostatic and hedonic satiety pathways.

2. Calcitonin Receptors (CTR): Cagrilintide directly engages calcitonin receptor isoforms, triggering downstream cAMP accumulation and signaling cascades that complement amylinergic pathways.

By engaging non-GLP-1 metabolic pathways, Cagrilintide provides a benchmark experimental model for researching multi-pathway synergy, delayed gastric emptying kinetics, postprandial glucagon suppression, and energy expenditure modulation.

Key Research Applications

• Dual Receptor Signaling (DACRA Kinetics): Investigating cAMP generation and downstream intracellular signaling through heterodimeric amylin and calcitonin receptors.

• Central Appetite & Satiety Circuits: Evaluating hindbrain neural activation, reduction of hedonic feeding behaviors, and food intake suppression in preclinical animal models.

• Multi-Incretin Co-Agonism Cross-Talk: Studying the additive and synergistic effects of combining amylinergic agonists with incretin receptor mimetics (such as GLP-1 or GIP/GLP-1 dual agonists) on body composition and glucose metabolism.

• Gastric Motility & Postprandial Dynamics: Measuring postprandial glucose excursions, rate of gastric emptying, and nutrient uptake kinetics.

Product Specifications & Quality Assurance